摘要
目的评价注射用尤瑞克林对急性脑梗死的临床疗效及安全性。方法根据1995年第四届全国脑血管病会议制订的诊断标准,选取急性脑梗死患者100例,入选病例随机分为两组各50例,对照组患者给予缺血性脑卒中基础治疗;治疗组患者除给予基础治疗外,予注射用尤瑞克林0.15PNA,分别于治疗前、治疗7d及治疗14d行NIHSS评分,并对治疗前后肝肾功能、凝血功能及出血事件作比较。结果治疗7d两组NIHSS评分差异无统计学意义(P>0.05);治疗14d治疗组NIHSS评分较对照组明显下降,差异有统计学意义(P<0.05);两组肝肾功能损害、凝血功能及出血事件差异无统计学意义(P>0.05)。结论尤瑞克林治疗急性脑梗死患者安全有效,优于单纯使用缺血性脑卒中基础治疗。
Objective To evaluate the clinical efficacy and safety of urinary kallidinogenase injection in patients with acute cerebral infarction.Methods One hundred patients with acute cerebral infarction were included in this trial,which were randomly divided into two groups.Patients in the control group （n=50） were treated with basic therapy,while those in the treatment group （n=50） were treated with urinary kal l idinogenase injection and basic therapy.NIHSS score were evaluated before treatment,7 days and 14 days after treatment,respectively.Hepatic function,renal function,coagulation function and hemorrhagic event were recorded before and after treatment.Results No significant difference was in NIHSS sore found 7 d after treatment （P＞0.05）,while 14 days after treatment,NIHSS score in the treatment group was significantly lower than that in the control group （P＜0.05）.No significant difference was found before and after treatment on hepatic,renal,coagulation impairment and hemorrhagic event （P＜0.05）.Conclusion Urinary kallidinogenase injection is effective and safe for patients with acute cerebral infarction,which is better than single use of basic therapy.
出处
《海南医学》
CAS
2013年第16期2350-2351,共2页
Hainan Medical Journal
关键词
尤瑞克林
脑梗死
临床疗效
安全性
Urinary kallidinogenase
Cerebral infarction
Clinical efficacy
Safety
